New coronavirus infection COVID-19 in a patient after kidney allotransplantation


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The article describes a clinical case of a new covid-19 coronavirus infection in a patient receiving immunosuppressive therapy after allotransplantation of a cadaveric kidney. in the present observation, the course of covid-19 was manifested by bilateral pneumonia with respiratory failure, which required the use of active therapy with antiviral drugs, complicated by a nephrotoxic effect with the correction of immunosuppressive therapy.

全文:

受限制的访问

作者简介

N. Frolova

Moscow city research and practice center for Nephrology and pathology of transplanted kidneys Moscow City Hospital 52

Email: nadiya.frolova@yandex.ru
PhD in Medical Sciences, Deputy Chief Physician for Nephrology Moscow, Russian Federation

S. Usatyuk

Moscow city research and practice center for Nephrology and pathology of transplanted kidneys Moscow City Hospital 52

Head of the Nephrology Department № 2 Moscow, Russian Federation

L. Artyukhina

Moscow city research and practice center for Nephrology and pathology of transplanted kidneys Moscow City Hospital 52

PhD in Medical Sciences, Head of the Nephrology Department № 1 (Transplant Kidney Pathology) Moscow, Russian Federation

O. Kotenko

Moscow city research and practice center for Nephrology and pathology of transplanted kidneys Moscow City Hospital 52

PhD in Medical Sciences, Head Moscow, Russian Federation

V. Mayorov

Moscow city research and practice center for Nephrology and pathology of transplanted kidneys Moscow City Hospital 52

Doctor at the Nephrology Department № 2 Moscow, Russian Federation

M. Lysenko

Moscow city research and practice center for Nephrology and pathology of transplanted kidneys Moscow City Hospital 52

Doctor of Medical Sciences, Chief Physician of the City Clinical Hospital № 52 of the Moscow Healthcare Department, Professor at the, Department of General Therapy, Faculty of Continuous Professional Education Moscow, Russian Federation

参考

  1. Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-1062.
  2. Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
  3. de Wilde A.H., Zevenhoven-Dobbe J.C., van der Meer Y. et al. Cyclosporin A inhibits the replication of diverse coronaviruses. J. Gen. Virol. 2011;92:2542-2548.
  4. Tanaka Y., Sato Y, Sasaki T. Suppression of coronavirus replication by cyclophilin inhibitors. Viruses. 2013;5:1250-1260.
  5. Banerjee D., Popoola J., Shah S. et al. COVID-19 infection in kidney transplant recipients. Kidney International (2020):inpress 1-7.
  6. Cao B. et al. N. Engl. J. Med. 382, 1787-1799 (2020).
  7. Yao X., Ye F., Zhang M. et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. 2020 March 9.
  8. J. Geleris Y., Sun J. Platt et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N. Engl. J. Med. 2020;382:1-7.
  9. Bhatraju P.K., Ghassemieh B.J., Michelle Nichols et al. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series N. Engl. J. Med. 2020;382:2012-2202.
  10. Mehta P., McAuley D.F., Brown M., Sanchez E., Tatter sail R.S., Manson J.J. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033-1034.
  11. Mark C. Genovese, James D. McKay, Evgeny L. Nasonov, Eduardo F. Mysler,Nilzio A. da Silva. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to diseasemodifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study// Arthritis and Rheumatism. 2008;58:2968-2980.
  12. Jones G, Sebba A., Gu J, Lowenstein M.B., Calvo A., Gomez-Reino J.J., Siri D.A., Tomsic M. et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Annals of the Rheumatic Diseases. 2010 69(1):88-96.
  13. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 6 (28.04.2020)

补充文件

附件文件
动作
1. JATS XML
下载